Belluscura (BELL) Competitors GBX 0.75 0.00 (0.00%) As of 07/2/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsBuy This Stock BELL vs. SUN, MHC, MXCT, DEMG, NIOX, SN, EKF, CREO, IUG, and NCYTShould you be buying Belluscura stock or one of its competitors? The main competitors of Belluscura include Surgical Innovations Group (SUN), MyHealthChecked (MHC), MaxCyte (MXCT), Deltex Medical Group (DEMG), NIOX Group (NIOX), Smith & Nephew (SN), EKF Diagnostics (EKF), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), and Novacyt (NCYT). These companies are all part of the "medical devices" industry. Belluscura vs. Its Competitors Surgical Innovations Group MyHealthChecked MaxCyte Deltex Medical Group NIOX Group Smith & Nephew EKF Diagnostics Creo Medical Group Intelligent Ultrasound Group Novacyt Surgical Innovations Group (LON:SUN) and Belluscura (LON:BELL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability. Which has stronger valuation and earnings, SUN or BELL? Surgical Innovations Group has higher revenue and earnings than Belluscura. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurgical Innovations Group£12.54M0.53N/AN/AN/ABelluscura£2.87M0.66-£29.55M-£9.37-0.08 Is SUN or BELL more profitable? Surgical Innovations Group has a net margin of -4.96% compared to Belluscura's net margin of -1,030.73%. Surgical Innovations Group's return on equity of -6.04% beat Belluscura's return on equity.Company Net Margins Return on Equity Return on Assets Surgical Innovations Group-4.96% -6.04% -3.03% Belluscura -1,030.73%-102.62%-43.53% Do institutionals & insiders hold more shares of SUN or BELL? 25.8% of Surgical Innovations Group shares are held by institutional investors. Comparatively, 6.3% of Belluscura shares are held by institutional investors. 67.2% of Surgical Innovations Group shares are held by company insiders. Comparatively, 56.3% of Belluscura shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, SUN or BELL? Surgical Innovations Group has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Belluscura has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Does the media prefer SUN or BELL? In the previous week, Surgical Innovations Group's average media sentiment score of 0.57 beat Belluscura's score of 0.00 indicating that Surgical Innovations Group is being referred to more favorably in the media. Company Overall Sentiment Surgical Innovations Group Positive Belluscura Neutral SummarySurgical Innovations Group beats Belluscura on 7 of the 10 factors compared between the two stocks. Get Belluscura News Delivered to You Automatically Sign up to receive the latest news and ratings for BELL and its competitors with MarketBeat's FREE daily newsletter. Email Address BELL vs. The Competition Export to ExcelMetricBelluscuraMedical Devices IndustryMedical SectorLON ExchangeMarket Cap£1.89M£3.41B£5.50B£2.96BDividend YieldN/A2.44%5.38%5.02%P/E Ratio-0.0872.9727.60146.59Price / Sales0.66103.14369.09240,167.53Price / Cash8.0015.9936.6327.97Price / Book0.063.858.055.30Net Income-£29.55M£132.05M£3.18B£5.90B7 Day PerformanceN/A10.51%2.82%0.92%1 Month PerformanceN/A7.95%3.70%5.20%1 Year Performance-94.83%14.17%35.41%80.76% Belluscura Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BELLBelluscuraN/AGBX 0.75flatN/A-95.0%£1.89M£2.87M-0.0824Gap UpSUNSurgical Innovations GroupN/AGBX 0.71+1.4%N/A+67.1%£6.62M£12.54M-21.1180Gap UpMHCMyHealthCheckedN/AGBX 10-7.0%N/A+5.3%£5.20M£9.43M-4.9916Negative NewsEarnings ReportGap DownMXCTMaxCyteN/AGBX 2.17-0.5%N/A-99.3%£2.86M£57.52M-0.0880Gap DownHigh Trading VolumeDEMGDeltex Medical GroupN/AN/AN/AN/A£187K£1.76M-0.1537Gap UpHigh Trading VolumeNIOXNIOX Group2.9553 of 5 starsGBX 68+0.3%GBX 90+32.4%-0.9%£27.93B£3.53B2,806.2492Positive NewsSNSmith & Nephew3.6835 of 5 starsGBX 1,105-1.3%GBX 7,840+609.5%+13.6%£12.11B£7.08B39.7818,452High Trading VolumeEKFEKF DiagnosticsN/AGBX 26-0.8%N/A-8.1%£115.56M£49.91M24.20356CREOCreo Medical GroupN/AGBX 12.75-3.8%N/A-61.8%£51.54M£33.87M-2.02279IUGIntelligent Ultrasound GroupN/AN/AN/AN/A£42.76M£6.57M-18.9165NCYTNovacytN/AGBX 41.49-1.7%N/A-12.3%£28.67M£18.12M-0.76120Positive News Related Companies and Tools Related Companies SUN Competitors MHC Competitors MXCT Competitors DEMG Competitors NIOX Competitors SN Competitors EKF Competitors CREO Competitors IUG Competitors NCYT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:BELL) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belluscura plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belluscura With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
